On May 22, 2014, TG Therapeutics, Inc. (NASDAQ:TGTX), announced upcoming presentations of clinical data for TG-1101, the Company’s next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company’s novel, once-daily PI3k delta inhibitor, at the 19th Congress of the European Hematology Association (EHA), being held June 12 – 15, 2014 in Milan, Italy. TG Therapeutics, Inc. (NASDAQ:TGTX), weekly performance is 5.11%. On last trading day company shares ended up $5.35. Analysts mean target price for the company is $12.50. TG Therapeutics, Inc. (NASDAQ:TGTX), distance from 50-day simple moving average (SMA50) is -8.32%.
On May 14, 2014, Transcept Pharmaceuticals Inc (NASDAQ:TSPT),announced that its board of directors declared a special cash dividend of $1.33 per share on the Company’s common stock. Payment will be made on June 3, 2014, to stockholders of record at the close of business on May 26, 2014. Transcept Pharmaceuticals Inc (NASDAQ:TSPT), advanced 5.23% in last trading session and ended the day on $3.22. TSPT, return on assets is -34.00%. Transcept Pharmaceuticals Inc (NASDAQ:TSPT), quarterly performance is -2.72%.
MannKind Corporation (NASDAQ:MNKD), VP Juergen Martens unloaded 76,899 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $7.50, for a total transaction of $576,742.50. Following the completion of the transaction, the vice president now directly owns 139,024 shares in the company, valued at approximately $1,042,680. MannKind Corporation (NASDAQ:MNKD), shares moved up 0.13% in last trading session and was closed at $7.77, while trading in range of $ 7.51 – 7.89. MannKind Corporation (NASDAQ:MNKD), year to date (YTD) performance is 49.42%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares fell 0.16% to $6.34. The company presented at the UBS Global Healthcare Conference being held in New York. Harvey J. Berger, M.D., chairman and chief executive officer, provided overview of company’s business on May 20, 2014, at 4:00 p.m. (ET). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), ended the last trading day at $6.30. Company weekly volatility is calculated as 3.98% and price to cash ratio as 6.43. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), showed a negative weekly performance of -0.94%.
On May 19, 2014, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA),fell 6.3% after the company reported a net loss per share of 12 cents in the Q1 of 2014. Arena had incurred a narrower loss of 9 cents in the year-ago quarter. Arena Pharma recorded Q1 revenues of $2.9 million benefiting from revenues recorded for its obesity drug, Belviq. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), net profit margin is -30.20% and weekly performance is -3.73%. On last trading day company shares ended up $6.19. Analysts mean target price for the company is $7.83. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), distance from 50-day simple moving average (SMA50) is -3.30%.
Leave a Reply